Navigation Links
Boston Scientific Launches Innovative Device Used to Prevent Stone Migration in Urologic Procedures
Date:4/2/2012

NATICK, Mass., April 2, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces the launch of its BackStop® Gel, a new technology designed to prevent stone migration during procedures used to break up and retrieve urinary stones.  The Company is now marketing the product in the U.S. and select international markets.

BackStop Gel is a water-soluble polymer that urologists inject into the ureter to form a plug behind the stone, preventing migration of stone fragments of all sizes.  Stone migration is a common clinical challenge during stone extraction and can result in increased procedure time, lower stone-free rates and increased need for secondary procedures.  The BackStop Gel is placed with a catheter, which is then removed to free up space in the operative field.  Unlike prior generations of antiretropulsion devices, BackStop Gel is designed without mechanical components susceptible to damage from devices used to fragment the stone.  Upon completion of the procedure, the BackStop Gel is designed to dissolve with conventional irrigation.

"I have found that using BackStop Gel in the ureter helps prevent the migration of stones and increases the success rate of stone removal," said Dianne Sacco, M.D., Director of Kidney Stone Program, Massachusetts General Hospital in Boston.  "This product provides a non-traumatic plug, which enhances the use of lithotripsy devices to successfully fragment and retrieve stones."  

"We are focused on offering minimally invasive and cost-effective medical devices that improve patient outcomes," said Michael Phalen, Executive Vice President and President of the Boston Scientific MedSurg Division.  "The BackStop Gel demonstrates this focus by providing a clinically effective method for urologists to manage the common problem of stone migration during treatment procedur
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Annual Biotech and Healthcare Conferences Being Held in Boston MA, Summer 2012
2. Boston Scientific Announces Launch of PROMUS Element™ Platinum Chromium Stent System in Japan
3. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston on March 7, 2012
4. Boston Scientific Announces First Implants of TELIGEN® Implantable Defibrillator in China
5. Boston Scientific Receives Industrys First FDA Approval for Drug-Eluting Coronary Stent Use in Heart Attack Patients
6. Boston Scientific Launches Innovative Crossing Device to Treat Complete Blockages in Peripheral Arteries
7. Boston Scientific to Participate in Leerink Swann 2012 Global Healthcare Conference
8. Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe
9. Boston IVF Pioneers Worlds First Needle-Free Saliva Test Used in Infertility Treatment; Patient Friendly Monitoring Replaces Daily Blood Tests
10. Boston Scientific Announces Favorable Ruling in Patent Infringement Case
11. Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) ... are the highlights: , Sales in local ... prior year. Reported sales decreased 4% as currency reduced ... Net earnings per diluted share as reported (EPS) were ... EPS was $2.80 , an increase of 9% ...
(Date:7/30/2015)... July 30, 2015  EP Global Communications, Inc. (Public ... recently contacted the Company about discussing EPGL,s electronic ... as Monday, August 3, 2015.  Novartis CEO ... that the coming electronic contact lens market could ... the next several years.  Novartis partnered with Google ...
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the second quarter ending June 30, 2015. ... the organization.  We are excited to be near the ... ever conducted with topline results expected in the fourth ... PTC Therapeutics, Inc. "Translarna is now commercially available in ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10
... Biosciences, a segment of BD (Becton, Dickinson and Company) (NYSE: ... Cytometer, a flexible, reliable and scalable system that can analyze ... research applications.   “We engineered cutting-edge innovation ... three foundations in mind,” said James Glasscock, President of Cell ...
... 2011 Ann Arbor SPARK recently celebrated the conclusion of ... a reception.  At the Ann Arbor SPARK Boot Camp Celebration, ... Camp" winner, based on the quality of its investor pitch ... though the Ann Arbor SPARK Business Accelerator.   ...
Cached Medicine Technology:BD Biosciences Launches New Cell Analyzer to Streamline Research Workflow 2BD Biosciences Launches New Cell Analyzer to Streamline Research Workflow 3Brio Device Awarded Best of Ann Arbor SPARK's Boot Camp 2
(Date:7/31/2015)... ... July 31, 2015 , ... Indosoft, Inc., is pleased to announce a ... Q-Suite is their flagship contact center ACD system for Asterisk-based call centers . ... shows the script components to the agent only when wanted, and allows for validation ...
(Date:7/31/2015)... Minneapolis, Minn. (PRWEB) , ... July 31, 2015 ... ... software, is selected as a contributor for LeadingAge’s Center for Aging Services Technologies ... studies designed to help long-term and post-acute care providers understand the benefits of ...
(Date:7/31/2015)... ... July 31, 2015 , ... The ... Karmanos Center for Natural Birth . The Karmanos Center for Natural Birth ... childbirth experience. With nurses and caregivers that are trained in holistic birth approaches, ...
(Date:7/31/2015)... OR (PRWEB) , ... July 31, 2015 , ... New ... Granary District Stage Amphitheater in McMinnville, Oregon August 15th, 2015 from 9am – 12pm. ... an exciting and important day for the entire community as the culmination of months ...
(Date:7/31/2015)... ... July 31, 2015 , ... An ... from NBC talked about a woman’s unfortunate experience having cosmetic skin procedures done ... face, which resulted in blistering, swelling, bruising, and pain. This woman’s experience is ...
Breaking Medicine News(10 mins):Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 2Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 3
... 2012)When combined with other treatments, the drug cetuximabwhich works ... been shown to extend survival in certain types of ... percent of colorectal cancer patientsspecifically those who carry a ... to the drug. Researchers at Fox Chase Cancer ...
... the next generation of global health scientists, Fogarty International ... Health are building a network of U.S. academic institutions ... a significant mentored research experience in a developing country. ... over the next five years to support 400 early-career ...
... autoimmune diseases also display a tendency to develop atherosclerosis ... arteries. Clinical researchers at LMU, in collaboration with colleagues ... to explain the connection between the two types of ... of immune cells called plasmacytoid dendritic cells (pDCs). pDCs ...
... ,People with metal-on-metal hip replacements do not have an increased ... receive the device, according to a new study. However, ... Universities of Bristol and Exeter in the U.K. report. ... and Wales, which contains records on more than 1 million ...
... News) -- A new study finds that preteen girls ... experience side effects after receiving the human papillomavirus (HPV) vaccine, ... are similar to those associated with other vaccines. U.S. ... to 26, within two weeks after they received the Gardasil ...
... April 3 (HealthDay News) -- Adding the drug cetuximab (brand ... colon cancer did not improve disease-free survival in patients, a ... who undergo surgery have a 50 percent chance of cure, ... leucovorin, fluorouracil and oxaliplatin (a regimen known as FOLFOX) after ...
Cached Medicine News:Health News:Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance 2Health News:NIH awards $20 million over 5 years to train next generation of global health researchers 2Health News:NIH awards $20 million over 5 years to train next generation of global health researchers 3Health News:The long arm of the dendritic cell 2Health News:The long arm of the dendritic cell 3Health News:No Added Cancer Risk From Hip Replacement Materials: Study 2Health News:Preteens More Likely to Report HPV Vaccine Side Effects 2Health News:Experimental Chemo Combo for Colon Cancer Disappoints 2
... tasks and delivers consistently reliable ... and ensure testing accuracy in ... automated reticulocyte counts and three-dimensional ... sensitivity, specificity and efficiency in ...
... staff scheduling solution that streamlines and ... the synchronization and interface of workforce ... maintains staff schedules and replacements; tracks ... shift and work location schedules; and ...
... A first of its kind product, ... most appealing colors and state-of-the-art SPECT technology ... cardiology system. The exclusive, contoured patient chair ... cardiac scanning. A relaxed patient moves ...
... Series of Cryoablation Catheters combines the safeguard ... the two-stage cooling system of the CryoCor ... of cryoenergy to the ablation site. CryoCor's ... create the transmural lesions necessary to permanently ...
Medicine Products: